CD8A and neoplasm: PI3Kδ blockade with Idelalisib likewise increased tumor cell depletion and decreased exhaustion in our setting, in line with its reported ability to modulate T‐cell differentiation, enrich for less differentiated cytotoxic CD8+ subsets, reduce Tregs, and lower exhaustion marker expression.36, 53